Precigen (PGEN) director Kirk sells shares worth $12.3 million

Director Randal J. Kirk of Precigen, Inc. (NASDAQ:PGEN) recently sold 2,966,293 shares of common stock over three days, according to a Form 4 filing with the Securities and Exchange Commission. The sales, which occurred between November 19 and November 21, 2025, generated approximately $12.3 million. The transactions come as InvestingPro data shows PGEN has experienced a 20% decline over the past week, despite posting a remarkable 330% return over the last year.

On November 19, Kirk sold 1,086,153 shares at a weighted average price of $4.47, for a total value of $4,854,003. The prices for these shares ranged from $4.31 to $4.68. The following day, November 20, he sold 942,832 shares at a weighted average price of $4.08, for a total value of $3,847,755 with prices ranging from $3.90 to $4.42. On November 21, Kirk sold 937,308 shares at $3.83, for a total value of $3,590,889. PGEN currently trades at $3.89, with analyst price targets ranging from $8 to $9, suggesting significant upside potential according to InvestingPro data.

The shares were indirectly owned through Kapital Joe, LLC. Following these transactions, Kirk continues to indirectly hold a significant number of Precigen shares through various entities including R.J. Kirk DOT, Parkview 2020, and Third Security, LLC. Precigen, with a market cap of $1.36 billion, currently operates with a moderate debt level and maintains strong liquidity with a current ratio of 4.04. For deeper insights into PGEN’s financial health and comprehensive analysis, check out the Pro Research Report available on InvestingPro.

In other recent news, Precigen Inc. reported its third-quarter 2025 earnings, which showed a notable revenue beat but a significant miss on earnings per share (EPS). The company achieved revenue of $2.92 million, far exceeding the forecast of $900,000. However, it recorded a net loss of $1.06 per share, which was considerably higher than the expected loss of $0.09 per share. This discrepancy was attributed mainly to non-recurring accounting items. Despite the EPS miss, Citizens reiterated its Market Outperform rating for Precigen, maintaining an $8.00 price target. The research firm noted promising early signs for the launch of Precigen’s PAPZIMEOS therapy, with patients being scheduled for treatment and significant demand observed. These developments highlight a mix of financial challenges and potential growth opportunities for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.